甲状腺激素水平与1型糖尿病患者植入的胰腺内胚层细胞成熟相关
在正在进行的临床试验中,于7个中心之一接受治疗的所有1型糖尿病患者中检测循环三碘甲状腺原氨酸和甲状腺素水平,分析其与C肽、胰高血糖素水平及植入胰腺内胚层细胞(PECs)细胞命运的关系。结果显示两种甲状腺激素均与细胞获得成熟胰岛素分泌表型的比例显著相关,且与植入后循环胰高血糖素水平呈负相关;小鼠中甲状腺功能亢进使PECs更快成熟为胰岛素生成细胞,表型与甲状腺功能正常小鼠中的PECs相似。
要点
- 甲状腺激素水平与植入PECs获得成熟胰岛素生成表型的细胞比例显著相关。
- 甲状腺激素水平与植入后循环胰高血糖素水平呈负相关。
- 作者认为甲状腺激素辅助治疗可能优化部分PEC受者的细胞结局。
核心结论
- 这些数据凸显甲状腺激素在1型糖尿病患者PEC治疗中的相关性,并提示甲状腺激素辅助治疗可能优化部分PEC受者的细胞结局。
研究设计与样本
- 在正在进行的临床试验的7个中心之一,测量所有接受治疗患者循环三碘甲状腺原氨酸和甲状腺素水平,分析其与C肽、胰高血糖素水平及植入PECs细胞命运的关系。
- 小鼠实验中,甲状腺功能亢进导致PECs更快成熟为胰岛素生成细胞,表型与甲状腺功能正常小鼠中的PECs相似。
主要发现
- 三碘甲状腺原氨酸和甲状腺素水平均与细胞获得成熟胰岛素生成表型的比例显著相关。
- 甲状腺激素水平与植入后循环胰高血糖素水平呈负相关,提示甲状腺激素使PECs倾向于胰岛素生成而非胰高血糖素生成的命运。
关键数值与推荐
- 原文未报告具体数值、阈值或统计量。
临床怎么用
- 作者认为,甲状腺激素辅助治疗可能优化部分PEC受者的细胞结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Macroencapsulated pancreatic endoderm cells (PECs) can reverse diabetes in rodents and preclinical studies revealed that thyroid hormones in vitro and in vivo bias PECs to differentiate into insulin-producing cells. In an ongoing clinical trial, PECs implanted in macroencapsulation devices into patients with type 1 diabetes were safe but yielded heterogeneous outcomes. Though most patients developed meal responsive C-peptide, levels were heterogeneous and explanted grafts had variable numbers of surviving cells with variable distribution of endocrine cells. METHODS: We measured circulating triiodothyronine and thyroxine levels in all patients treated at 1 of the 7 sites of the ongoing clinical trial and determined if thyroid hormone levels were associated with the C-peptide or glucagon levels and cell fate of implanted PECs. RESULTS: Both triiodothyronine and thyroxine levels were significantly associated with the proportion of cells that adopted an insulin-producing fate with a mature phenotype. Thyroid hormone levels were inversely correlated to circulating glucagon levels after implantation, suggesting that thyroid hormones lead PECs to favor an insulin-producing fate over a glucagon-producing fate. In mice, hyperthyroidism led to more rapid maturation of PECs into insulin-producing cells similar in phenotype to PECs in euthyroid mice. CONCLUSION: These data highlight the relevance of thyroid hormones in the context of PEC therapy in patients with type 1 diabetes and suggest that a thyroid hormone adjuvant therapy may optimize cell outcomes in some PEC recipients.
引用
- Ramzy A, Saber N, Bruin JE, et al. Thyroid Hormone Levels Correlate With the Maturation of Implanted Pancreatic Endoderm Cells in Patients With Type 1 Diabetes. J Clin Endocrinol Metab. 2024. PMID: 37671625. doi:10.1210/clinem/dgad499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。